Abstract:Aim: To discuss treatment with eribulin in clinical practice outside a clinical trial. Methods: Archives of patients treated for metastatic breast cancer were reviewed and 21 patients treated with the new chemotherapeutic eribulin mesylate, a synthetic analog of a natural marine product, were identified. Information on patients' characteristics and treatment outcomes was extracted. Treatment with eribulin mesylate was initiated at the recommended dose of 1.4 mg/m(2) on days 1 and 8 of a 21-day cycle in 17 patients and at a decreased dose of 1.1 mg/m(2) on days 1 and 8 of a 21-day cycle in 4 patients due to comorbidities and frailty. Efficacy of the drug was evaluated using the revised Response Evaluation Criteria in Solid Tumors criteria. Progression-Free Survival and overall survival (OS) were calculated using the Kaplan-Meier method starting from the date of eribulin therapy initiation to the date of disease progression documentation or death, respectively. Results: The median age of patients at the time of eribulin mesylate treatment was 53 years (range 34-75). Sixteen patients had estrogen receptor (ER) and/or partial response (PR) positive disease and 5 had ER/PR negative disease (all triple negative). Eight patients had received 2 or 3 previous lines of chemotherapy for metastatic disease and 13 patients had received 4 or more lines of treatment. The median number of cycles of eribulin received was 3 (range 1-16 years). All patients, except one, discontinued treatment due to progressive disease and one patient due to adverse effects. Six patients had a dose reduction due to side effects. All patients had progressed at the time of the report with a median time to progression of 3 mo (range 1 to 14 mo). Fifteen patients had died with a median OS of 7 mo (range 1-18 mo). Six patients were alive with a median follow-up of 13.5 mo (range 7 to 19 mo). Conclusion: This series of patients confirms the activity of eribulin in a heavily pre-treated metastatic breast cancer population consistent with phase II and III trials.

Gram-Scale Synthesis of the C14–C23 Fragment of Eribulin

A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin B

Reassembly of the Biosynthetic Gene Cluster Enables High Epothilone Yield in Engineered Schlegelella Brevitalea.

Synthesis of C3-C12 Fragment of 24-Demethylbafilomycin C1 Via Anti-Selective Aldol Condensation As the Key Stereocontrol Step

Total Synthesis of Plagiochin G and Derivatives As Potential Cancer Chemopreventive Agents.

A Transition Metal-Free Approach to a Regioselective Total Synthesis of the Natural Product Derivative 6-Methylellipticine, a Potent Anticancer Agent

Synthesis of C13-C25 fragment of 24-demethylbafilomycin C1 via diastereoselective aldol reactions of a ketone boron enolate as the key step

Synthetic Studies On Pseudolaric Acid B: Enantioselective Synthesis Of C4,C10-Di-Epi-Trans-Fused [5-7]-Bicyclic Skeleton

A Concise and Practical Semisynthesis of Ecteinascidin 743 and (–)‐Jorumycin

Concise Gram-Scale Synthesis of Euphorikanin A Skeleton Through a Domino Ring-Closing Metathesis Strategy

Synthesis of C21‐C41 fragment of the reported structure of Neaumycin B

Asymmetric synthesis of erythro-8-O-4’-neolignan Machilin C

Total Syntheses of Epothilones A and B Via A Macrolactonization-Based Strategy

Eribulin for heavily pre-treated metastatic breast cancer patients

Development of a Scalable Synthesis Toward a KRAS G12C Inhibitor Building Block Bearing an All-Carbon Quaternary Stereocenter, Part 1: from Discovery Route to Kilogram-Scale Production

Heterologous Production of Epothilone C and D in Escherichia coli

Development of an improved and facile synthesis route of the FGFR inhibitor erdafitinib

Tumor selective self-assembled nanomicelles of carbohydrate-epothilone B conjugate for targeted chemotherapy

Multigram Scale, Chiron-Based Synthesis of Sacubitril

Simplified Hybrids of Two Anticancer Bistetrahydroisoquinoline Alkaloids Ecteinascidin 743 and Cribrostatin 4 and Inhibitory Activity Against Proliferation of Cancer Cells.

Research progress on the pharmacological mechanism, in vivo metabolism and structural modification of Erianin